Keystone Symposia | Scientific Conferences on Biomedical and Life Science Topics

Molecular and Cellular Biology of Immune Escape in Cancer (J6)

Organizer(s): George C. Prendergast and Dmitry I. Gabrilovich
February 7 - 12, 2010
Keystone Resort · Keystone, Colorado
Abstract Deadline: October 7, 2009
Late Abstract Deadline: November 6, 2009
Scholarship Deadline: October 7, 2009
Early Registration Deadline: December 7, 2009

Sponsored by Astellas Pharma Inc. and Genentech BioOncology

Joint meeting: Role of Inflammation in Oncogenesis (J5)
NOTE: Registration for meeting allows attendance at joint meeting (pending space availability).

This meeting took place in the 2010 season.

For a complete list of the meetings for the upcoming/current season,
see our meeting list, or search for a meeting.

Summary of Meeting
It is now widely recognized that the immune microenvironment of a tumor provides critical support in determining its progression versus dormancy or destruction. To gain immune benefits the tumor must evolve mechanisms of immune escape. Study of this crucial process requires cross-fertilization between molecular cell biologists and tumor immunologists who do not tend to interact. This problem is also integrated with the problem of cancer inflammation that has captured the attention of tumor biologists focused on transgenic mouse models and clinical settings. Thus, we propose a unique conference – the first of its kind – to integrate perspectives from a diverse set of researchers in cancer, immunology, and molecular therapeutics and to focus specifically on immune escape and tumor-induced immune suppression as a multidisciplinary problem. Cancer is initiated by the accumulation of genetic and epigenetic changes in a normal cell, but its progression depends on the stromal and immune microenvironment of the initiated cell. While intrinsic signals within the initiated cell drive neoplastic transformation and genomic plasticity, extrinsic signals delivered by immune cells are critical in dictating whether progression versus dormancy or destruction of an initiated lesion takes place, and also whether metastasis may occur. The high degree of genomic plasticity in cancer cells permits them to develop sophisticated ways to prevent the immune system from recognizing and eliminating tumor cells. It has become increasingly clear in recent years that abnormalities in the immune system that are induced by tumors not only hamper natural anti-tumor immune surveillance but also limit the efficacy of immunotherapy and even traditional chemotherapy and radiotherapy. Thus, tumor-induced immune abnormalities may not only impact the clinical course of disease but also the prospects for its therapeutic management. Recent results indicate that we are on the verge of a real breakthrough in our understanding of how tumors thwart the immune system and how correcting immune escape could vastly improve cancer therapy. However, at present the available mechanistic information presents a somewhat convoluted picture that includes some seemingly contradictory elements. While this situation is a natural stage of development in the field, there is nevertheless a pressing need to define key questions and organize their development in coherent ways that can speed improvements in cancer therapy.

Sunday, February 7
3:00 - 7:30 PM	Registration	Longs Peak Foyer
6:30 - 7:30 PM	Refreshments	Longs Peak Foyer
7:30 - 9:30 PM	Keynote Session (Joint)	Grays/Longs Peak
	* Nina Bhardwaj, New York University School of Medicine
	* Dmitry I. Gabrilovich, University of South Florida
	* George C. Prendergast, Lankenau Institute for Medical Research
	* Giorgio Trinchieri, National Cancer Institute at Frederick
	Robert D. Schreiber, Washington University School of Medicine Co-Evolution of Immunoediting on Oncogenesis during Tumor Formation
	Frances R. Balkwill, Queen Mary University of London, Barts and The London Medical School Inflammatory Cytokines and Autocrine Tumor-Promoting Networks
Monday, February 8
7:00 - 8:00 AM	Breakfast	Quandary
8:00 - 11:15 AM	Tumor Microenvironment and Immune Escape (Joint) This session will be focused on how stromal cells, inflammation, and angiogenesis support malignant progression, highlighting crucial roles for immune cells in contributing to these processes.	Grays/Longs Peak
	* Robert D. Schreiber, Washington University School of Medicine
	Lisa M. Coussens, University of California, San Francisco Role of Inflammation in Tumor Progression
	Claire E. Lewis, University of Sheffield Medical School Role of Macrophages in Tumor Progression and Response to Therapy
	Arya Biragyn, National Institute of Aging, National Institutes of Health Short Talk: Primary Breast Cancer Actively Generates Regulatory T and B Cells (Tregs and Bregs) to Facilitate Lung Metastasis
	Gerard I. Evan, University of California, San Francisco Immune Function and Angiogenesis in Myc-mediated Tumor Formation
	Hans Schreiber, University of Chicago The Role of Tumor Stroma in Immune Escape of Cancer
	Esteban Celis, Moffitt Cancer Center Short Talk: Interferon-gamma Induced T Cell Epitope Purging: Another Mode of Tumor Immune Escape?
9:20 - 9:40 AM	Coffee Break	Longs Peak Foyer
11:15 AM -	On Own for Lunch and Recreation
11:15 AM - 1:00 PM	Poster Setup	Quandary
1:00 - 10:00 PM	Poster Viewing	Quandary
2:30 - 4:30 PM	Workshop 1: Regulation of Immune Escape by Microenvironment This session will deepen understanding of the critical role of the tumor microenvironment in driving malignant progression.	Longs Peak
	* Dmitry I. Gabrilovich, University of South Florida
	Srinivas Nagaraj, University of South Florida, College of Medicine Regulation of Myeloid-Derived Suppressor Cell Activity in Cancer by CD4+ T Cells
	Cassie K. Chou, University of Washington Abrogation of TGFbeta Signaling Leads to Increased Persistence of Prostate Self/Tumor Antigen Specific CD8 T Cells but does not Completely Prevent Tolerization
	Luca Vago, IRCCS H San Raffaele Loss of Mismatched HLA as a Mechanism of Leukemia Immune Escape in Family Haploidentical and Unrelated HSCT
	Philippe Foubert, University of California, San Diego Blockade of Myeloid Cell Trafficking by Inhibiting a PI3-Kinase gamma-alpha4 Integrin Activation Pathway Stimulates Anti-Tumor Immunity
	Sheng Wei, Moffitt Cancer Center Myeloid-Derived Suppressor Cells (MDSC) are Effectors of Bone Marrow Suppression in Lower Risk Myelodysplastic Syndromes (MDS)
	Michael S. Leibowitz, University of Pittsburgh TAP1/2 Downregulation and CTL Evasion is Independent of STAT3 Activation in Head and Neck Cancer Cells
4:30 - 5:00 PM	Coffee Available	Longs Peak Foyer
5:00 - 7:00 PM	Antigen-Specific Mechanisms of Tumor Escape This session will be focused on molecular and cellular mechanisms associated with role of antigens in tumor escape. Topics include tumor antigen diversity, molecular mechanisms of defective antigen presentation by tumor cells, dendritic cells and T cell tolerance.	Longs Peak
	* Hans Schreiber, University of Chicago
	Thomas Blankenstein, Max Delbruck Center for Molecular Medicine No Escape
	Michael R. Shurin, University of Pittsburgh Dendritic Cells in Immune Escape in Cancer
	Richard A. Flavell, Yale University School of Medicine TGF-beta Signaling in Tumoral Immune Suppression
	Andrew D.M. Kaiser, Netherlands Cancer Institute Short Talk: Low Tumor-Antigen Density Leads to PD-L1/PD-1 Mediated Suppression of Partially Exhausted CD8+ T Cells
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Quandary
7:30 - 10:00 PM	Poster Session 1	Quandary
Tuesday, February 9
7:00 - 8:00 AM	Breakfast	Quandary
8:00 - 11:15 AM	Myeloid Cells in Immune Suppression and Tumor Progression This session will focus on the molecular and cellular mechanisms of immunosuppression by different types of myeloid cells.	Longs Peak
	* Mario P. Colombo, Fondazione IRCCS Istituto Nazionale Tumori
	Dmitry I. Gabrilovich, University of South Florida Regulation of Myeloid-Derived Suppressor Cells in Cancer
	David H. Munn, Medical College of Georgia Indoleamine 2,3-Dioxygenase in Tumor Immune Escape


	David R. Gibb, Virginia Commonwealth University and
	Sheinei Jamal Saleem, Virginia Commonwealth University Short Talk: A Novel Model of Myeloid-Derived Suppression of the Anti-Tumor Response: Overexpression of ADAM10 Promotes Myeloid-Derived Suppressor Cell Expansion in a Tumor-Free Environment
	Vincenzo Bronte, Istituto Oncologico Veneto Forced Myelopoiesis and Immune Deviation in Cancer
	Ling Qi, Cornell University Short Talk: The Metabolic Function of Myeloid-Derived Suppressor Cells in Obesity
	Cong Yan, Indiana University School of Medicine Short Talk: Apoptotic Inhibition of Myeloid Cells Causes MDSC Expansion and Lung Tumorigenesis
	Anna Wasiuk, Dartmouth College Short Talk: Mast Cells as Regulators of Adaptive Immunity to Tumors
9:20 - 9:40 AM	Coffee Break	Longs Peak Foyer
11:15 AM -	On Own for Lunch and Recreation
11:15 AM - 1:00 PM	Poster Setup	Quandary
1:00 - 10:00 PM	Poster Viewing	Quandary
4:30 - 5:00 PM	Coffee Available	Longs Peak Foyer
5:00 - 7:00 PM	Regulatory T and NKT Cells in Immune Escape This session is focused on molecular and cellular mechanisms of regulatory T cell function in cancers. Specific topics can include novel findings on the role of classical Treg in cancer, different types of Tregs, and role of NKT.	Longs Peak
	* Vincenzo Bronte, Istituto Oncologico Veneto
	Harald von Boehmer, Harvard Medical School In vivo Induction of Antigen-Specific Regulatory T Cells to Prevent Unwanted Immunity
	Rong-Fu Wang, Baylor College of Medicine Immunosuppressive gammadelta Treg and other Immune Cells and their Functional Regulation through Innate Immune Signaling
	Mario P. Colombo, Fondazione IRCCS Istituto Nazionale Tumori OX40 Costimulation in Treg Functions
	Jay A. Berzofsky, National Cancer Institute, National Institutes of Health Short Talk: Tipping the Balance in the NKT Cell Regulation of Tumor Immunity
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Quandary
7:30 - 10:00 PM	Poster Session 2	Quandary
Wednesday, February 10
7:00 - 8:00 AM	Breakfast	Quandary
8:00 - 11:15 AM	Transcriptional Regulation of Immune Escape (Joint) Session will discuss regulation of gene expression implicated in tumor progression and immune escape, including possible modifier effects and relationship to metastastic efficiency.	Grays/Longs Peak
	* George C. Prendergast, Lankenau Institute for Medical Research
	Hua E. Yu, Beckman Research Institute, City of Hope STAT3 in Cancer Inflammation and Immune Escape
	Erwin F. Wagner, Spanish National Cancer Research Centre Stress-responsive and context dependent transcription factor complex
	Mitsugu Fujita, University of Pittsburgh Cancer Institute A Pivotal Role of Type-1 Interferons in Anti-glioma Immunosurveillance
	Thomas F. Gajewski, University of Chicago Transcriptional regulation of T cell anergy: Implications for cancer immunotherapy
	Michael Karin, University of California, San Diego Tumor elicited inflammation and lymphocyte infiltrates in metastatic progression
	Jahan Khalili, MD Anderson Cancer Center Short Talk: The Role of B-raf V600E Mutation on PD-1 Ligand Expression in Melanocytic nevi
9:20 - 9:40 AM	Coffee Break	Longs Peak Foyer
11:15 AM -	On Own for Lunch and Recreation
11:15 AM - 1:00 PM	Poster Setup	Quandary
1:00 - 10:00 PM	Poster Viewing	Quandary
2:30 - 4:30 PM	Workshop 2: Tumor Recruitment of Immune Cells: Roles in Tumor Progression and Immune Escape Consider roles for MDSCs, B cells, mast cells, microvesicle transfer, etc.	Longs Peak
	* Michael R. Shurin, University of Pittsburgh
	Courtney Smith, Lankenau Institute for Medical Research Indoleamine 2,3-Dioxygenase (IDO) Supports Metastatic Outgrowth of the 4T1 Breast Cancer Mouse Model
	Melody A. Swartz, Swiss Federal Institute of Technology (EPFL) Lymph Node Mimicry by Tumors Promotes Immunological Tolerance
	Stephanie Watkins, National Cancer Institute, National Institutes of Health Prostate Tumor-Associated Dendritic Cell Induction of Tolerance and Suppressor Activity in Tumor-Infiltrating CTLs is Associated with FOXO3a Expression
	Rongcun Yang, Nankai University Suppressor of Cytokine Signaling-3 (SOCS3) Downregulates the Ability of Pyruvate Kinase Type M2 to Cause Dendritic Cell Dysfunction
	Kyle C. McKenna, University of Pittsburgh Short Talk: Inhibited Function of Intratumoral F4/80+ Macrophages Contributes to the Failure of CD8+ CTL to Control Ocular Tumor Development
	Andreas Herrmann, Beckman Research Institute Short Talk: Stat3 is a Molecular Target for Improving Adoptive T cell Therapy
4:30 - 5:00 PM	Coffee Available	Longs Peak Foyer
5:00 - 7:00 PM	Immune Inhibitory Receptors in Cancer	Longs Peak
	* Augusto C. Ochoa, Louisiana State University Health Sciences Center
	Drew M. Pardoll, Johns Hopkins University School of Medicine Mechanism of T-Cell Tolerance in Cancer Mediated by Inhibitory Receptors

	Hyam I. Levitsky, Johns Hopkins School of Medicine Mechanism of T-Cell Tolerance in Cancer
	Dario A.A. Vignali, St. Jude Children's Research Hospital Short Talk: Official title unknown. Topic was IL-35 and its role in regulation of T cell function
	George Coukos, University of Pennsylvania Hypoxia Recruits Regulatory T Cells via the CCL28 Chemokine to Promote Tolerance and Angiogenesis in Cancer
	Daniel Hirschhorn-Cymerman, Memorial Sloan-Kettering Cancer Center Short Talk: OX40 Engagement and Chemotherapy Combination Provides Potent Anti-Tumor Immunity with Concomitant Regulatory T Cell Apoptosis
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Quandary
7:30 - 10:00 PM	Poster Session 3	Quandary
Thursday, February 11
7:00 - 8:00 AM	Breakfast	Quandary
8:00 - 11:15 AM	Metabolic Pathways Involved in Immune Escape This session will be focused on the role of metabolism of carbohydrates, lipids, arginine, tryptophan, and exosomes in tumor escape.	Longs Peak
	* Drew M. Pardoll, Johns Hopkins University School of Medicine
	Gabriel A. Rabinovich, Instituto de Biologia y Medicina Experimental 'Turning Sweet' on Immunity: Galectin-Glycan Interactions in T-Cell and Dendritic Cell Physiology
	Suzanne Ostrand-Rosenberg, University of Maryland Myeloid Cells, Inflammation, and Anti-Tumor Immunity: Not an Auspicious Combination
	Linglin Yang, University of Maryland, Baltimore County Short Talk: Indoleamine 2,3-Dioxygenase (IDO) Contributes to Myeloid-Derived Suppressor Cell- Mediated Tumor Suppression through Interleukin-6 Signaling Pathway
	Augusto C. Ochoa, Louisiana State University Health Sciences Center Arginine Depletion by MDSC in vivo, a Mechanism of Tumor Escape
	Licia Rivoltini, Fondazione IRCCS Istituto Nazionale Tumori Tumor-Derived Microvesicles and Immune Defects in Human Cancer
	Jonathan D. Silk, University of Oxford Short Talk: A Novel Amino Acid Transporter Induced by Expression of Indoleamine 2,3 Dioxygenase in Tumors
9:20 - 9:40 AM	Coffee Break	Longs Peak Foyer
11:15 AM -	On Own for Lunch and Recreation
2:30 - 4:30 PM	Workshop 3: Novel Strategies to Reverse Immune Escape in Cancer Will discuss novel approaches to reversal of immune defects in cancer. Topics may include cytokines supporting productive immune response, block of inhibitory cytokines and receptors, regulation of immune responses via toll-like receptors, etc.	Longs Peak

	Juan R. Cubillos-Ruiz, Dartmouth Medical School siRNA Delivery through Novel TLR5-Agonist Polyethylenimine Reprograms Tumor-Associated Regulatory Dendritic Cells to Elicit Therapeutic Immunity
	Viktor Umansky, German Cancer Research Center Blocking of Myeloid Derived Suppressor Cell (MDSC) Functions Results in Antitumor Effects in Ret Transgenic Mouse Melanoma Model
	Xiangdong Liu, Incyte Corporation INCB24360, a Potent and Selective Inhibitor of Indoleamine 2,3-dioxygenase (IDO) for Cancer Immunotherapy
	Ge Ma, Mount Sinai School of Medicine Paired Immunoglobin Like Receptor-B (PIRB) Regulates the Suppressive Function and M1 versus M2 Differentiation of MDSC
	Carl E. Ruby, Earle A. Chiles Research Institute Characterizing the Effect of Aging in Tumor-Bearing Hosts Treated with OX40 Agonists

	Thorbald van Hall, Leiden University Medical Center A Novel Category of Tumor Antigens Enable CTL Immunity to Tumor Escape Variants
4:30 - 5:00 PM	Coffee Available	Longs Peak Foyer
5:00 - 7:15 PM	Therapeutic Development to Correct Immune Escape in Cancer This session will discuss preclinical and clinical development of different approaches to counter immune suppressive mechanisms in cancer.	Longs Peak
	* Hyam I. Levitsky, Johns Hopkins School of Medicine
	George C. Prendergast, Lankenau Institute for Medical Research Regulation and Therapeutic Inhibition of IDO/IDO2 in Cancer
	Alexander J. Muller, Lankenau Institute for Medical Research Short Talk: IDO Contributes to Pathologies Associated with Chronic Inflammation
	Jedd D. Wolchok, Memorial Sloan-Kettering Cancer Center The Whys and Wherefores of CTLA-4 Blockade

	Suzanne L. Topalian, Johns Hopkins University School of Medicine Modulating Anti-tumor Immunity through Checkpoint Blockade: B7-H1/PD-1 Interactions
	Jeffrey Weber, H. Lee Moffitt Cancer Center Regulation of Immune Responses in Cancer via Checkpoint Blockade of Negative Receptors in Melanoma
7:15 - 8:15 PM	Social Hour w/ Lite Bites	Quandary
8:15 - 11:00 PM	Entertainment	Quandary
Friday, February 12
	Departure

*Session Chair †Speaker invited, not yet responded.